Comprehensive molecular characterization of gastric adenocarcinoma
- PMID: 25079317
- PMCID: PMC4170219
- DOI: 10.1038/nature13480
Comprehensive molecular characterization of gastric adenocarcinoma
Abstract
Gastric cancer is a leading cause of cancer deaths, but analysis of its molecular and clinical characteristics has been complicated by histological and aetiological heterogeneity. Here we describe a comprehensive molecular evaluation of 295 primary gastric adenocarcinomas as part of The Cancer Genome Atlas (TCGA) project. We propose a molecular classification dividing gastric cancer into four subtypes: tumours positive for Epstein-Barr virus, which display recurrent PIK3CA mutations, extreme DNA hypermethylation, and amplification of JAK2, CD274 (also known as PD-L1) and PDCD1LG2 (also known as PD-L2); microsatellite unstable tumours, which show elevated mutation rates, including mutations of genes encoding targetable oncogenic signalling proteins; genomically stable tumours, which are enriched for the diffuse histological variant and mutations of RHOA or fusions involving RHO-family GTPase-activating proteins; and tumours with chromosomal instability, which show marked aneuploidy and focal amplification of receptor tyrosine kinases. Identification of these subtypes provides a roadmap for patient stratification and trials of targeted therapies.
Conflict of interest statement
The author declare no competing financial interests.
Figures
Comment in
-
Genetics: new molecular classification of gastric adenocarcinoma proposed by The Cancer Genome Atlas.Nat Rev Clin Oncol. 2014 Sep;11(9):499. doi: 10.1038/nrclinonc.2014.138. Epub 2014 Aug 12. Nat Rev Clin Oncol. 2014. PMID: 25113841 No abstract available.
-
Four subtypes of gastric cancer identified.Cancer Discov. 2014 Oct;4(10):1108-9. doi: 10.1158/2159-8290.CD-NB2014-125. Epub 2014 Aug 14. Cancer Discov. 2014. PMID: 25274664 No abstract available.
-
Epstein-Barr virus-associated gastric carcinoma with heterogeneous EBER positivity accompanied by distinctive morphological cellular changes.Pathol Int. 2020 May;70(5):306-308. doi: 10.1111/pin.12920. Epub 2020 Mar 15. Pathol Int. 2020. PMID: 32173925 No abstract available.
-
Lessons in gastric adenocarcinoma from TCGA.Nat Rev Cancer. 2023 Oct;23(10):655. doi: 10.1038/s41568-023-00606-1. Nat Rev Cancer. 2023. PMID: 37474705 No abstract available.
Similar articles
-
[New molecular classification of colorectal cancer, pancreatic cancer and stomach cancer: Towards "à la carte" treatment?].Bull Cancer. 2016 Jul-Aug;103(7-8):643-50. doi: 10.1016/j.bulcan.2016.05.007. Epub 2016 Jun 23. Bull Cancer. 2016. PMID: 27345450 Review. French.
-
Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus-associated gastric carcinoma.Hum Pathol. 2016 Jul;53:25-34. doi: 10.1016/j.humpath.2016.02.007. Epub 2016 Mar 4. Hum Pathol. 2016. PMID: 26980034
-
Epstein-Barr Virus-Associated Gastric Carcinoma: Use of Host Cell Machineries and Somatic Gene Mutations.Pathobiology. 2015;82(5):212-23. doi: 10.1159/000434683. Epub 2015 Aug 25. Pathobiology. 2015. PMID: 26337667 Review.
-
Genomic assays for Epstein-Barr virus-positive gastric adenocarcinoma.Exp Mol Med. 2015 Jan 23;47(1):e134. doi: 10.1038/emm.2014.93. Exp Mol Med. 2015. PMID: 25613731 Free PMC article. Review.
-
Epstein-Barr virus-associated gastric cancer: disease that requires special approach.Gastric Cancer. 2020 Nov;23(6):951-960. doi: 10.1007/s10120-020-01095-z. Epub 2020 Jun 8. Gastric Cancer. 2020. PMID: 32514646 Review.
Cited by
-
Deciphering the potential role of post-translational modifications of histones in gastrointestinal cancers: a proteomics-based review with therapeutic challenges and opportunities.Front Oncol. 2024 Oct 21;14:1481426. doi: 10.3389/fonc.2024.1481426. eCollection 2024. Front Oncol. 2024. PMID: 39497715 Free PMC article. Review.
-
Construction and evaluation of a polygenic hazard score for prognostic assessment in localized gastric cancer.Fundam Res. 2022 Nov 9;4(5):1331-1338. doi: 10.1016/j.fmre.2022.09.031. eCollection 2024 Sep. Fundam Res. 2022. PMID: 39431145 Free PMC article.
-
Radiosensitivity index emerges as a potential biomarker for combined radiotherapy and immunotherapy.NPJ Genom Med. 2021 Jun 2;6(1):40. doi: 10.1038/s41525-021-00200-0. NPJ Genom Med. 2021. PMID: 34078917 Free PMC article.
-
Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis.Clin Cancer Res. 2015 Apr 15;21(8):1944-50. doi: 10.1158/1078-0432.CCR-14-2600. Epub 2015 Jan 26. Clin Cancer Res. 2015. PMID: 25623214 Free PMC article.
-
Prognostic and Predictive Value of Cadherin 11 for Patients with Gastric Cancer and Its Correlation with Tumor Microenvironment: Results from Microarray Analysis.Biomed Res Int. 2020 Jun 26;2020:8107478. doi: 10.1155/2020/8107478. eCollection 2020. Biomed Res Int. 2020. PMID: 32685527 Free PMC article.
References
-
- Ferlay, J. et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide. IARC CancerBase 11, http://globocan.iarc.fr, accessed on January 15, 2014 (2013)
-
- WHO Classification of Tumours of the Digestive System 4th edn. (International Agency for Research on Cancer, 2010)
Publication types
MeSH terms
Substances
Grants and funding
- P30CA16672/CA/NCI NIH HHS/United States
- U24 CA143882/CA/NCI NIH HHS/United States
- 5U24CA143840/CA/NCI NIH HHS/United States
- R01 HG005690/HG/NHGRI NIH HHS/United States
- 5U24CA143835/CA/NCI NIH HHS/United States
- U24 CA143843/CA/NCI NIH HHS/United States
- U24 CA143883/CA/NCI NIH HHS/United States
- U24 CA143867/CA/NCI NIH HHS/United States
- 5U24CA143882/CA/NCI NIH HHS/United States
- 5U24CA143799/CA/NCI NIH HHS/United States
- P30 CA016672/CA/NCI NIH HHS/United States
- K99 CA166729/CA/NCI NIH HHS/United States
- P01 CA028842/CA/NCI NIH HHS/United States
- 5U24CA143843/CA/NCI NIH HHS/United States
- U54 HG003067/HG/NHGRI NIH HHS/United States
- U54HG003273/HG/NHGRI NIH HHS/United States
- U24 CA143835/CA/NCI NIH HHS/United States
- 5U24CA143867/CA/NCI NIH HHS/United States
- P30 CA006973/CA/NCI NIH HHS/United States
- 5U24CA143866/CA/NCI NIH HHS/United States
- U24 CA143866/CA/NCI NIH HHS/United States
- K08 CA134931/CA/NCI NIH HHS/United States
- R01 HG007069/HG/NHGRI NIH HHS/United States
- U54HG003067/HG/NHGRI NIH HHS/United States
- U24 CA143845/CA/NCI NIH HHS/United States
- U24 CA143799/CA/NCI NIH HHS/United States
- P50 CA098258/CA/NCI NIH HHS/United States
- 5U24CA144025/CA/NCI NIH HHS/United States
- U54 HG003273/HG/NHGRI NIH HHS/United States
- P30 CA008748/CA/NCI NIH HHS/United States
- U24 CA144025/CA/NCI NIH HHS/United States
- 5U24CA143848/CA/NCI NIH HHS/United States
- U54HG003079/HG/NHGRI NIH HHS/United States
- U24 CA180951/CA/NCI NIH HHS/United States
- U24 CA143840/CA/NCI NIH HHS/United States
- R01 CA180006/CA/NCI NIH HHS/United States
- U24 CA143858/CA/NCI NIH HHS/United States
- 5U24CA143858/CA/NCI NIH HHS/United States
- U24 CA143848/CA/NCI NIH HHS/United States
- U24 CA126543/CA/NCI NIH HHS/United States
- ImNIH/Intramural NIH HHS/United States
- 5U24CA143845/CA/NCI NIH HHS/United States
- U54 HG003079/HG/NHGRI NIH HHS/United States
- 5U24CA143883/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous